In this perspective, we [21] and others [22-25] have demonstrated that in CML patients treated with IM there is a transient increase in bone-formation markers that could be linked to inhibition of PDGFR signaling. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.